Clear cell renal carcinoma treated with cabozantinib in the METEOR study – case study
05/2017
MUDr. Jana Katolická, Ph.D.1, MUDr. Sabina Svobodová1, MUDr. Jiří Vaniček, Ph.D.2, Mgr. Pavlína Prosecká3
1 Onkologicko-chirurgické oddělení, FN u svaté Anny, Brno
2 Klinika zobrazovacích metod, FN u svaté Anny, Brno
3 Oddělení klinických studií, Mezinárodní centrum klinického výzkumu, FN u svaté Anny, Brno
SUMMARY
Targeted treatment is currently a standard therapeutic method for metastatic clear cell renal carcinoma. Cabozantinib is an oral tyrosine kinase inhibitor including MET, VEGFR, and AXL. In a randomized phase III METEOR study, prolongation of survival in patients following prior VEGFR treatment with tyrosine kinase inhibitors has been demonstrated.
KEY WORDS
metastatic light cell carcinoma of the kidney, cabozantinib
The full article is only available to subscribers
Become a regular subscriber to our Oncological Review...